vs
Esperion Therapeutics, Inc.（ESPR）与Perimeter Solutions, Inc.（PRM）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是Perimeter Solutions, Inc.的1.6倍（$168.4M vs $102.8M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 19.2%），过去两年Perimeter Solutions, Inc.的营收复合增速更高（31.9% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Perimeter Solutions是一家以色列云与网络安全企业，专为各类机构打造基于零信任架构的安全远程网络方案，其技术可替代VPN、防火墙等传统安全硬件设备，助力企业简化网络安全部署，提升远程访问的安全性与效率。
ESPR vs PRM — 直观对比
营收规模更大
ESPR
是对方的1.6倍
$102.8M
营收增速更快
ESPR
高出124.6%
19.2%
两年增速更快
PRM
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $102.8M |
| 净利润 | — | $-140.2M |
| 毛利率 | — | 45.2% |
| 营业利润率 | 50.6% | -160.7% |
| 净利率 | — | -136.5% |
| 营收同比 | 143.7% | 19.2% |
| 净利润同比 | — | -197.3% |
| 每股收益（稀释后） | $0.32 | $-0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRPRM
| Q4 25 | $168.4M | $102.8M | ||
| Q3 25 | $87.3M | $315.4M | ||
| Q2 25 | $82.4M | $162.6M | ||
| Q1 25 | $65.0M | $72.0M | ||
| Q4 24 | $69.1M | $86.2M | ||
| Q3 24 | $51.6M | $288.4M | ||
| Q2 24 | $73.8M | $127.3M | ||
| Q1 24 | $137.7M | $59.0M |
净利润ESPRPRM
| Q4 25 | — | $-140.2M | ||
| Q3 25 | $-31.3M | $-90.7M | ||
| Q2 25 | $-12.7M | $-32.2M | ||
| Q1 25 | $-40.5M | $56.7M | ||
| Q4 24 | — | $144.2M | ||
| Q3 24 | $-29.5M | $-89.2M | ||
| Q2 24 | $-61.9M | $21.6M | ||
| Q1 24 | $61.0M | $-82.6M |
毛利率ESPRPRM
| Q4 25 | — | 45.2% | ||
| Q3 25 | — | 63.1% | ||
| Q2 25 | — | 62.4% | ||
| Q1 25 | — | 39.1% | ||
| Q4 24 | — | 48.6% | ||
| Q3 24 | — | 62.8% | ||
| Q2 24 | — | 57.6% | ||
| Q1 24 | — | 35.1% |
营业利润率ESPRPRM
| Q4 25 | 50.6% | -160.7% | ||
| Q3 25 | -11.4% | -27.7% | ||
| Q2 25 | 8.6% | -16.1% | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | 71.1% | ||
| Q3 24 | -31.0% | -12.2% | ||
| Q2 24 | 3.5% | 35.4% | ||
| Q1 24 | 52.5% | -126.8% |
净利率ESPRPRM
| Q4 25 | — | -136.5% | ||
| Q3 25 | -35.9% | -28.7% | ||
| Q2 25 | -15.4% | -19.8% | ||
| Q1 25 | -62.2% | 78.7% | ||
| Q4 24 | — | 167.2% | ||
| Q3 24 | -57.2% | -30.9% | ||
| Q2 24 | -83.9% | 17.0% | ||
| Q1 24 | 44.3% | -139.8% |
每股收益（稀释后）ESPRPRM
| Q4 25 | $0.32 | $-0.89 | ||
| Q3 25 | $-0.16 | $-0.62 | ||
| Q2 25 | $-0.06 | $-0.22 | ||
| Q1 25 | $-0.21 | $0.36 | ||
| Q4 24 | $-0.14 | $1.00 | ||
| Q3 24 | $-0.15 | $-0.61 | ||
| Q2 24 | $-0.33 | $0.14 | ||
| Q1 24 | $0.34 | $-0.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $325.9M |
| 总债务越低越好 | — | $669.1M |
| 股东权益账面价值 | $-302.0M | $1.1B |
| 总资产 | $465.9M | $2.7B |
| 负债/权益比越低杠杆越低 | — | 0.59× |
8季度趋势，按日历期对齐
现金及短期投资ESPRPRM
| Q4 25 | $167.9M | $325.9M | ||
| Q3 25 | $92.4M | $340.6M | ||
| Q2 25 | $86.1M | $140.7M | ||
| Q1 25 | $114.6M | $200.1M | ||
| Q4 24 | $144.8M | $198.5M | ||
| Q3 24 | $144.7M | $223.1M | ||
| Q2 24 | $189.3M | $43.2M | ||
| Q1 24 | $226.6M | $38.7M |
总债务ESPRPRM
| Q4 25 | — | $669.1M | ||
| Q3 25 | — | $668.8M | ||
| Q2 25 | — | $668.4M | ||
| Q1 25 | — | $668.1M | ||
| Q4 24 | — | $667.8M | ||
| Q3 24 | — | $667.4M | ||
| Q2 24 | — | $667.1M | ||
| Q1 24 | — | $666.8M |
股东权益ESPRPRM
| Q4 25 | $-302.0M | $1.1B | ||
| Q3 25 | $-451.4M | $1.1B | ||
| Q2 25 | $-433.5M | $1.2B | ||
| Q1 25 | $-426.2M | $1.2B | ||
| Q4 24 | $-388.7M | $1.2B | ||
| Q3 24 | $-370.2M | $1.0B | ||
| Q2 24 | $-344.2M | $1.1B | ||
| Q1 24 | $-294.3M | $1.1B |
总资产ESPRPRM
| Q4 25 | $465.9M | $2.7B | ||
| Q3 25 | $364.0M | $2.6B | ||
| Q2 25 | $347.1M | $2.5B | ||
| Q1 25 | $324.0M | $2.4B | ||
| Q4 24 | $343.8M | $2.4B | ||
| Q3 24 | $314.1M | $2.5B | ||
| Q2 24 | $352.3M | $2.3B | ||
| Q1 24 | $373.1M | $2.3B |
负债/权益比ESPRPRM
| Q4 25 | — | 0.59× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | 0.67× | ||
| Q2 24 | — | 0.62× | ||
| Q1 24 | — | 0.63× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $18.6M |
| 自由现金流经营现金流 - 资本支出 | — | $11.6M |
| 自由现金流率自由现金流/营收 | — | 11.3% |
| 资本支出强度资本支出/营收 | 0.0% | 6.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $208.6M |
8季度趋势，按日历期对齐
经营现金流ESPRPRM
| Q4 25 | $45.2M | $18.6M | ||
| Q3 25 | $-4.3M | $198.7M | ||
| Q2 25 | $-31.4M | $-2.9M | ||
| Q1 25 | $-22.6M | $23.7M | ||
| Q4 24 | $-35.0M | $-6.0M | ||
| Q3 24 | $-35.3M | $183.0M | ||
| Q2 24 | $-7.2M | $8.6M | ||
| Q1 24 | $53.8M | $2.8M |
自由现金流ESPRPRM
| Q4 25 | — | $11.6M | ||
| Q3 25 | — | $193.6M | ||
| Q2 25 | — | $-15.6M | ||
| Q1 25 | — | $18.9M | ||
| Q4 24 | — | $-12.4M | ||
| Q3 24 | $-35.5M | $179.1M | ||
| Q2 24 | $-7.3M | $5.0M | ||
| Q1 24 | $53.8M | $1.2M |
自由现金流率ESPRPRM
| Q4 25 | — | 11.3% | ||
| Q3 25 | — | 61.4% | ||
| Q2 25 | — | -9.6% | ||
| Q1 25 | — | 26.3% | ||
| Q4 24 | — | -14.4% | ||
| Q3 24 | -68.7% | 62.1% | ||
| Q2 24 | -9.9% | 3.9% | ||
| Q1 24 | 39.0% | 2.1% |
资本支出强度ESPRPRM
| Q4 25 | 0.0% | 6.8% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 7.8% | ||
| Q1 25 | 0.0% | 6.7% | ||
| Q4 24 | 0.0% | 7.5% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 0.1% | 2.9% | ||
| Q1 24 | 0.1% | 2.6% |
现金转化率ESPRPRM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | -0.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.40× | ||
| Q1 24 | 0.88× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PRM
| Products | $87.7M | 85% |
| Service And Other | $14.8M | 14% |
